RxDoctor Payments Data

Sarina Phatak, MD

Internal Medicine · Manchester, MONPI 1366556912

Payments from drug & device makers

$1,349in general payments, 2019–2025

Across 56 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$375
  • Lundbeck LLC$128
  • Lilly USA, LLC$127
  • Astellas Pharma US Inc$125
  • Pfizer$98
  • Novo Nordisk$92
  • plus $403 from 13 others

What the payments were for

  • Food & beverage$1,27294%
  • Education$776%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,349 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$69,044
Medicare patients
270
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban903$192,329
MyrbetriqMirabegron226$38,252
JanuviaSitagliptin Phosphate133$35,847
JardianceEmpagliflozin105$25,444
TrulicityDulaglutide28$24,753
OzempicSemaglutide23$23,093
Breo ElliptaFluticasone/Vilanterol40$17,287
TradjentaLinagliptin104$15,911
FarxigaDapagliflozin Propanediol76$15,837
LinzessLinaclotide27$15,474
XareltoRivaroxaban55$15,155
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$14,795
CreonLipase/Protease/Amylase27$14,423
Memantine Hcl495$13,804
Atorvastatin Calcium921$10,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$98$192,329903 claims
AbbVieLinzess, Creon, Restasis, Lumigan$375$45,018103 claims
Astellas Pharma US IncMyrbetriq$125$38,252226 claims
Novo NordiskOzempic, Fiasp$92$28,12738 claims
Lilly USA, LLCTrulicity$127$24,75328 claims
Johnson & JohnsonXarelto$17$15,15555 claims
Almatica Pharma LLCSertraline Hcl$17$8,704716 claims
Sumitomo Pharma America, Inc.Gemtesa$43$6,16750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Manchester

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →